Application No.: 09/164,568 2 Docket No.: 20052/1200518-US5

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1-81. (Canceled)
- 82. (New) A method for reducing T cell responsiveness *in vivo* to an autoantigen expressing cell, which method comprises administering to a subject in need of such treatment:
 - (a) an antigen-presenting cell that presents an autoantigen; and
 - (b) an anti-gp39 antibody which binds to an antigen, which antigen:
 - (i) is bound by a CD40-immunoglobulin (CD40-Ig) fusion protein;
 - (ii) is present on activated but not resting T-cells; and
 - (iii) has the same molecular weight as a protein precipitated by the CD40-Ig fusion protein,

wherein the anti-gp39 antibody is administered prior to, concurrent with, or subsequent to administration of the antigen-presenting cell in an amount effective to reduce T cell responsiveness to the antigen-presenting cell.

- 83. (New) The method of claim 82, wherein the antigen-presenting cell is selected from the group consisting of B lymphocytes, monocytes, dendritic cells, Langerhans cells, keratinocytes, endothelial cells, astrocytes, fibroblasts and oligodendrocytes.
- 84. (New) The method of claim 82, wherein the antigen-presenting cell is a B lymphocyte.

85. (New) The method of claim 84, wherein the B lymphocyte is an activated B lymphocyte.

- 86. (New) The method of claim 85, wherein the activated B lymphocyte is a splenic activated B lymphocyte.
- 87. (New) The method of claim 82, wherein the antigen-presenting cell is a lymphoid cell.
- 88. (New) The method of claim 82, wherein the antigen-presenting cell is a peripheral blood lymphocyte.
- 89. (New) The method of claim 82, wherein the antigen-presenting cell is a bone marrow lymphocyte.
- 90. (New) The method of claim 82, wherein the antigen-presenting cell is a Langerhans cell.
- 91. (New) The method of claim 82, wherein the antigen-presenting cell is a dendritic cell.
- 92. (New) The method of claim 82, wherein the anti-gp39 antibody is an anti-human anti-gp39 antibody.
- 93. (New) The method of claim 92, wherein the anti-human anti-gp39 antibody is humanized.
- 94. (New) The method of claim 92, wherein the anti-human anti-gp39 antibody is a chimeric anti-human anti-gp39 antibody containing human constant regions.